Clinical Trials Logo

Filter by:
NCT ID: NCT05055362 Completed - Clinical trials for Overweight and Obesity

Effect a Honey, Spice-blended Baked Good Has on Salivary Inflammation Markers in Adults: a Pilot Study

Start date: September 22, 2021
Phase: N/A
Study type: Interventional

The purpose of this research is to determine the effect a spiced-infused baked good has on inflammatory biomarkers in adults who are overweight and/or who has chronic kidney disease. Participants will be involved for 10 days in this research study.

NCT ID: NCT05055219 Completed - PreDiabetes Clinical Trials

Conventional and Metabolomic Predictors of Prediabetes & Insulin Resistance

Start date: June 2015
Phase:
Study type: Observational

The purpose of this study is to evaluate the longitudinal test performance of an array of conventional biomarkers of glycemia, including Hemoglobin A1c (HbA1c), and novel metabolomic biomarkers for identifying progression of glucose tolerance (normal to prediabetes or prediabetes to diabetes) in an overweight and obese pediatric cohort.

NCT ID: NCT05055141 Completed - Clinical trials for No Condition is the Focus of the Study

Enhancing Caregiver Empathy by Empowering Patients to Discuss Their Values

ENHANCE
Start date: December 12, 2018
Phase: N/A
Study type: Interventional

The aim of the ENHANCE study was to determine if an intervention focused on empowering medical inpatients to discuss their values and interests with their Cleveland Clinic Caregivers leads to greater caregiver empathy, improved patient experience, and improved Caregiver experience. The intervention patient participants received a poster where they were able to share things about themselves that they wanted their Caregivers to know. These posters were hung on the wall behind their bed. A few days later, they were given a survey to assess their experiences in the hospital. On the control floors, medicine patients were recruited a few days into their admission and administered a survey. CCF Caregivers completed surveys before the intervention period and afterward. Data collection is complete, data analysis is largely finished and a manuscript is in progress. 320 patients and 219 CCF Caregivers participated in the study.

NCT ID: NCT05055128 Completed - Erosive Esophagitis Clinical Trials

A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazole

Start date: August 11, 2021
Phase: Phase 2
Study type: Interventional

This study will be conducted in patients with erosive esophagitis due to gastro-esophageal reflux disease (GERD) Los Angeles (LA) grades C or D, and in patients with at least partial symptom response but still endoscopically unhealed (LA grades A or B) after 8 weeks history of standard treatment healing course with PPI, designed to support dose selection for Phase 3 and to investigate safety, tolerability, and healing rates after 4 weeks treatment of X842 or Lansoprazole, and symptom pattern during subsequent 4 weeks treatment with Lansoprazole.

NCT ID: NCT05055024 Completed - Narcolepsy Clinical Trials

An Open Label Study of NLS-2 (Mazindol Extended Release) in Subjects With Narcolepsy

Start date: October 26, 2021
Phase: Phase 2
Study type: Interventional

This is a multicenter, open-label extension of the clinical study NLS-1021, evaluating long-term safety, tolerability, pharmacokinetics (PK), and therapeutic response to treatment with NLS-2 in adult subjects with narcolepsy.

NCT ID: NCT05054998 Completed - Clinical trials for Metastatic Malignant Solid Neoplasm

Dual Time Point FDG PET/MRI Scan in Improving the Imaging Cancer Patients With Brain Metastases

Start date: August 3, 2018
Phase: Phase 4
Study type: Interventional

This phase IV trial studies how well delaying positron emission tomography (PET)/magnetic resonance imaging (MRI) scan after injection of fluorodeoxyglucose (FDG) can improve the imaging of patients with cancer that has spread to brain (brain metastases). FDG is a type of imaging agent that doctors use to help "see" the images on a scan more clearly. Delaying PET/MRI scan after injecting FDG may improve how well doctors can tell the difference between healthy and unhealthy tissue.

NCT ID: NCT05054569 Completed - Cancer Clinical Trials

Developing and Pre-Testing an eHealth Group Intervention for Young Adult Cancer Survivors

Start date: September 1, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to develop and pre-test an eHealth group intervention for young adult cancer survivors.

NCT ID: NCT05054374 Completed - Breast Cancer Clinical Trials

A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer

Start date: September 14, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study to find out whether mirdametinib is a safe treatment for people with advanced solid tumor cancer that has certain mutations. Researchers will look at whether mirdametinib on its own or in combination with the drug fulvestrant is a safe treatment that causes few or mild side effects in people with advanced solid tumor cancer.

NCT ID: NCT05054348 Completed - Solid Tumor, Adult Clinical Trials

First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors

Start date: September 30, 2021
Phase: Phase 1
Study type: Interventional

The goal of the clinical trial is to learn about safety, tolerability and preliminary efficacy of IO-108 as monotherapy or in combination with a PD-1 inhibitor in patients with advanced, metastatic solid tumors, and to find a dose of IO-108 that is safe and efficacious to be tested in patients with various solid tumors.

NCT ID: NCT05054218 Completed - Covid19 Clinical Trials

COVID-19 Immunogenicity of a Third Dose of mRNA-1273 Vaccine Among Cancer Patients

Start date: September 10, 2021
Phase:
Study type: Observational

Investigators will evaluate the immunogenicity of a third dose of mRNA-1273 SARS-CoV-2 vaccine among cancer patients receiving the recommended third vaccine dose